Compare TRAK & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | KLRS |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 144.9M |
| IPO Year | 1996 | N/A |
| Metric | TRAK | KLRS |
|---|---|---|
| Price | $8.08 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 103.6K | 80.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $44.22 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $2.14 |
| 52 Week High | $23.72 | $11.88 |
| Indicator | TRAK | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 43.62 |
| Support Level | $8.11 | $5.26 |
| Resistance Level | $9.02 | $7.18 |
| Average True Range (ATR) | 0.39 | 0.59 |
| MACD | 0.14 | 0.15 |
| Stochastic Oscillator | 69.37 | 47.09 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.